JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mardini, M.
Right arrow Articles by Rasmussen, H. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mardini, M.
Right arrow Articles by Rasmussen, H. H.

Vol. 297, Issue 2, 804-810, May 2001

Cyclosporine and FK506 Differentially Regulate the Sarcolemmal Na+-K+ Pump

Mahidi Mardini , Anastasia S. Mihailidou, Angela Wong and Helge H. Rasmussen

Department of Medicine, University of Sydney, Sydney, Australia (M.M., H.H.R.); Department of Cardiology, Royal North Shore Hospital, Sydney, Australia (M.M., A.S.M., H.H.R.); Department of Cardiology, Westmead Hospital, Sydney, Australia (M.M.); and Department of Pathology, St. Vincents Hospital, Sydney, Australia (A.W.)

Cyclosporine A (CsA) and FK506, important immunosuppressants, have been shown to inhibit the enzymatic equivalent of the Na+-K+ pump (Na+, K+-ATPase) in renal tissue. A similar effect in the heart may contribute to the adverse effects of these agents that include calcification, contractile dysfunction, and altered calcium handling. However, inhibition of the pump has not been demonstrated in cardiac myocytes. We isolated single ventricular myocytes from control rabbits and from rabbits administered CsA or FK506 for 1 week. Na+-K+ pump current (Ip) was measured using the whole-cell patch-clamp technique. When patch pipettes contained Na+ in a concentration ([Na]pip) near physiological intracellular levels mean Ip of cardiac myocytes from rabbits with serum CsA levels within the therapeutic range was significantly lower than mean Ip of cardiac myocytes from controls. Treatment had no effect on Ip measured using a [Na]pip expected to nearly saturate intracellular binding sites. The CsA-induced inhibition of Ip was dependent on the K+ concentration in pipette solutions. Mean Ip in myocytes from rabbits with serum levels of FK506 within the therapeutic range was similar to mean Ip in myocytes from controls, whereas FK506 in a dose inducing serum levels severalfold above the therapeutic range caused significant pump inhibition. Using ion-sensitive microelectrodes we showed the intracellular Na+ activity in papillary muscles isolated from rabbits treated with CsA was significantly higher than in papillary muscles from control rabbits, indicating that CsA causes pump inhibition in intact myocytes with a physiological intracellular milieu.


0022-3565/01/2972-0804$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
EndocrinologyHome page
A. S. Mihailidou, M. Mardini, and J. W. Funder
Rapid, Nongenomic Effects of Aldosterone in the Heart Mediated by {epsilon} Protein Kinase C
Endocrinology, February 1, 2004; 145(2): 773 - 780.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
M. J. McKenna, S. F. Fraser, J. L. Li, X. N. Wang, M. F. Carey, E. A. Side, J. Morton, G. I. Snell, K. Kjeldsen, and T. J. Williams
Impaired muscle Ca2+ and K+ regulation contribute to poor exercise performance post-lung transplantation
J Appl Physiol, October 1, 2003; 95(4): 1606 - 1616.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. S. Mihailidou, M. Mardini, J. W. Funder, and M. Raison
Mineralocorticoid and Angiotensin Receptor Antagonism During Hyperaldosteronemia
Hypertension, August 1, 2002; 40(2): 124 - 129.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.